Notice of Closed Meeting, 71068-71069 [2021-26955]
Download as PDF
<![CDATA[
jspears on DSK121TN23PROD with NOTICES1
71068
Federal Register / Vol. 86, No. 237 / Tuesday, December 14, 2021 / Notices
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
Written Public Comment: The docket
will be opened to receive written
comments on December 14, 2021.
Written comments must be received on
or before January 12, 2022.
Oral Public Comment: This meeting
will include time for members of the
public to make an oral comment. Oral
public comment will occur before any
scheduled votes including all votes
relevant to the ACIP’s Affordable Care
Act and Vaccines for Children Program
roles. Priority will be given to
individuals who submit a request to
make an oral public comment before the
meeting according to the procedures
below.
Procedure for Oral Public Comment:
All persons interested in making an oral
public comment at the January 12, 2022
ACIP meeting must submit a request at
https://www.cdc.gov/vaccines/acip/
meetings/ no later than 11:59 p.m., EST,
January 7, 2022, according to the
instructions provided.
If the number of persons requesting to
speak is greater than can be reasonably
accommodated during the scheduled
time, CDC will conduct a lottery to
determine the speakers for the
scheduled public comment session.
CDC staff will notify individuals
regarding their request to speak by email
by January 10, 2022. To accommodate
the significant interest in participation
in the oral public comment session of
ACIP meetings, each speaker will be
limited to 3 minutes, and each speaker
may only speak once per meeting.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
VerDate Sep<11>2014
18:24 Dec 13, 2021
Jkt 256001
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–26956 Filed 12–13–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Board of Scientific Counselors, Deputy
Director for Infectious Diseases (BSC,
DDID)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
CDC announces the following meeting
for the Board of Scientific Counselors,
Deputy Director for Infectious Diseases
(BSC, DDID). This virtual meeting is
open to the public via Zoom, limited
only by the space available, which is
500 seats. Pre-registration is required by
accessing the link below in the
addresses section.
DATES: The meeting will be held on
January 19–20, 2022, from 1:00 p.m. to
5:30 p.m., EST.
ADDRESSES: Zoom virtual meeting. Preregistration is required by accessing the
link at https://cdc.zoomgov.com/
webinar/register/WN_
vXuOtDbNQIycPMScOPKvKQ.
Instructions to access the meeting will
be provided following registration.
FOR FURTHER INFORMATION CONTACT:
Hilary Eiring, MPH, Designated Federal
Officer, CDC, 1600 Clifton Road NE,
Mailstop H24–12, Atlanta, Georgia
30329–4027, Telephone: (770) 488–
3901; Email: HEiring@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The Board provides advice
and guidance to the Secretary,
Department of Health and Human
Services; the Director, CDC; the Director
and the Deputy Director for Infectious
Diseases (DDID), CDC; and the Directors
of the National Center for Emerging and
Zoonotic Infectious Diseases, the
National Center for HIV, Viral Hepatitis,
STD, and TB Prevention, and the
National Center for Immunization and
Respiratory Diseases, CDC, in the
following areas: Strategies, goals, and
priorities for programs and research
within the national centers and monitor
SUMMARY:
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
the overall strategic direction and focus
of DDID and the national centers.
Matters To Be Considered: The agenda
will include updates and discussions on
recent outbreaks; updates and
discussions on CDC’s Center for
Forecasting and Outbreak Analytics,
advanced molecular detection program,
Data Modernization Initiative, and
CORE Health Equity Science and
Intervention Strategy; and other updates
and reports, including a brief report
back from the Board’s Food Safety
Modernization Act Surveillance
Working Group. Agenda items are
subject to change as priorities dictate.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–26954 Filed 12–13–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463.
Name of Committee: Safety and
Occupational Health Study Section (SOHSS),
National Institute for Occupational Safety
and Health (NIOSH).
Dates: February 16–17, 2022.
Time: 11:00 a.m.—5:00 p.m., EST.
Place: Teleconference.
Agenda: The meeting will convene to
address matters related to the conduct of
Study Section business and for the study
section to consider safety and occupational
health-related grant applications.
E:\FR\FM\14DEN1.SGM
14DEN1
Federal Register / Vol. 86, No. 237 / Tuesday, December 14, 2021 / Notices
For Further Information Contact: Michael
Goldcamp, Ph.D., Scientific Review Officer,
NIOSH, 1095 Willowdale Road, Morgantown,
WV 26506, Telephone: (304) 285–5951;
Email: MGoldcamp@cdc.gov.
The Director, Strategic Business Initiatives
Unit, Office of the Chief Operating Officer,
Centers for Disease Control and Prevention,
has been delegated the authority to sign
Federal Register notices pertaining to
announcements of meetings and other
committee management activities, for both
the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–26955 Filed 12–13–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–N–3758]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Expanded Access
to Investigational Drugs for Treatment
Use
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA, Agency, or we) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on information
collection associated with expanded
access to investigational drugs for
treatment use.
DATES: Submit either electronic or
written comments on the collection of
information by February 14, 2022.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before February 14,
2022. The https://www.regulations.gov
electronic filing system will accept
comments until 11:59 p.m. Eastern Time
at the end of February 14, 2022.
jspears on DSK121TN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
18:24 Dec 13, 2021
Jkt 256001
Comments received by mail/hand
delivery/courier (for written/paper
submissions) will be considered timely
if they are postmarked or the delivery
service acceptance receipt is on or
before that date.
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2018–N–3758 for ‘‘Agency Information
Collection Activities; Proposed
Collection; Comment Request;
Expanded Access Applications.’’
Received comments, those filed in a
timely manner (see ADDRESSES), will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
71069
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
FOR FURTHER INFORMATION CONTACT:
Amber Sanford, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–8867, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3521), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
E:\FR\FM\14DEN1.SGM
14DEN1
]]>Agencies
[Federal Register Volume 86, Number 237 (Tuesday, December 14, 2021)]
[Notices]
[Pages 71068-71069]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-26955]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Director, Strategic
Business Initiatives Unit, Office of the Chief Operating Officer, CDC,
pursuant to Public Law 92-463.
Name of Committee: Safety and Occupational Health Study Section
(SOHSS), National Institute for Occupational Safety and Health
(NIOSH).
Dates: February 16-17, 2022.
Time: 11:00 a.m.--5:00 p.m., EST.
Place: Teleconference.
Agenda: The meeting will convene to address matters related to
the conduct of Study Section business and for the study section to
consider safety and occupational health-related grant applications.
[[Page 71069]]
For Further Information Contact: Michael Goldcamp, Ph.D.,
Scientific Review Officer, NIOSH, 1095 Willowdale Road, Morgantown,
WV 26506, Telephone: (304) 285-5951; Email: [email protected].
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-26955 Filed 12-13-21; 8:45 am]
BILLING CODE 4163-18-P
